Summary of the Life Sciences SEIS
In order to provide investors with the best possible outcomes, the Deepbridge Life Sciences SEIS is an opportunity to secure potentially attractive returns by investing in a portfolio of early-stage life science companies, whilst taking advantage of the considerable income tax, capital gains tax, and inheritance tax benefits available under the Seed Enterprise Investment Scheme.
Our aim is to provide investors with access to a portfolio of investee companies aligned with investors’ goals and ambitions.
Providing seed investment to emerging companies operating in the life sciences sector, the Deepbridge Life Sciences SEIS seeks to fund companies with exciting new technologies that aim to satisfy the needs of large and growing markets. The overarching aim of the Deepbridge Life Sciences SEIS is to offer investors a diversified exposure to companies engaged in the development of therapeutics for the following areas:
- Anti-viral drug discovery and development
- Antibiotic drug discovery and development
- Neurodegenerative disease therapeutics
- Cancer diagnostics and therapeutics
- Autoimmune and other metabolic disorders therapies.
We also offer the Deepbridge Innovation SEIS fund, for more details on this click here.
In order to provide investors with the best possible outcomes, the investment strategy of the Deepbridge Life Sciences SEIS is for subscriptions to be invested in a portfolio of Investee Companies (subject to minimum allocation per investee company) that participate in (but are not restricted to) one of the following:
Deepbridge will also seek non-dilutive matched funding from regional development funds, as well as research grant funding, both provided on an unsecured basis. Deepbridge will add further value to Investee Companies by taking a seat on the Board of Directors and using an extensive industry network to access advice and commercial support to the business. Deepbridge may also co-invest alongside investors. Deepbridge may utilise the services of innovation management partners, major teaching hospitals, the NHS, incubators and accelerators. Third-party innovation development partners may take a significant minority equity position in those companies, in exchange for their services provided to such companies.
Alternative Investment Fund
HMRC Advance Assurance
Received before deployment into companies
Usually 6 monthly
250p for every 100p invested
5 – 7 years minimum
The Investment Team
Our Life Sciences SEIS investment team is dedicated to providing expert guidance and mentoring to our portfolio companies, ensuring they have an active and hands-on role in the development of the company. Further to this, our investment team is responsible for the extensive vetting and due diligence of prospective investee companies that are seeking funding.
Dr. Savvas Neophytou
Partner & Chief Investment Officer
Investment Director, Head of Life Sciences
Dr. Andrew Round
Investment Co-Ordinator – Life Sciences
There are no management charges levied on the investor at the point of investment for subscriptions received by a financial adviser, resulting in up to 100% allocation of subscription. This ensures up to 100% tax efﬁciency for investors. Deepbridge fees are paid by the Investee Companies and are disclosed in the Information Memorandum.
Please note that for direct investors (i.e. those that subscribe without a financial adviser involved), an additional charge of 2.5% including VAT will be deducted from the subscription to cover Deepbridge's costs associated with verifying the appropriateness of the Deepbridge EIS application.
Performance fee: an incentive fee of 20% of cash returned, in excess of 150% of the funds invested.
For clarification, once the Investor has received in cash the first 150 pence per 100 pence invested (ignoring any tax relief and representing a 50% Hurdle Rate on funds invested), any additional distributable cash will be paid as to 80% to the Investor and 20% to Deepbridge.
Independent reviews are available upon request.